The MyPathway trial, a phase IIA multiple basket study, also showed encouraging results with targeting ERBB2 amplification in heavily pretreated colorectal cancer patients: the combination of trastuzumab and pertuzumab was found to have a response rate of 37.5% [84]. Here, ERBB2 is linked to colorectal cancer.